Disclosure Outside the submitted work, SDN reported serving on end point adjudication committee for clinical trials sponsored by Alnylam, Intercept, Prokidney and Vertex, and consultant for AstraZeneca, Bayer, Boehringer Ingelheim, and Novartis
Acyclovir treatment of the chronic fatigue syndrome Lack of efficacy in a placebo-controlled trial
There is concern for the high incidence of weight gain with discontinuation." Internal Medicine "1
Therefore, proper titration schedules must be followed closely
In real life, people don't arrive with a neat label
More than half of the participants receiving tirzepatide lost 25% or more of their body weight during the trial period